Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 2, Pages 203-212Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.872987
Keywords
bioreactor; glycosylation; low cost vaccines; molecular farming; moss; oral immunization
Categories
Funding
- Deutscher Akademischer Austauschdienst
Ask authors/readers for more resources
The moss Physcomitrella patens has a number of advantages for the production of biopharmaceuticals, including: i) availability of standardized conditions for cultivation in bioreactors; ii) not being part of the food chain; iii) high biosafety; iv) availability of highly efficient transformation methods; v) a haploid, fully sequenced genome providing genetic stability and uniform expression; vi) efficient gene targeting at the nuclear level allows for the generation of mutants with specific post-translational modifications (e.g., glycosylation patterns); and vii) oral formulations are a viable approach as no toxic effects are attributed to ingestion of this moss. In the light of this panorama, this opinion paper analyzes the possibilities of using P. patens for the production of oral vaccines and presents some specific cases where its use may represent significant progress in the field of plant-based vaccine development. The advantages represented by putative adjuvant effects of endogenous secondary metabolites and producing specific glycosylation patterns are highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available